Seres Therapeutics, Inc. (MCRB)

Seres Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	58.85	30.79	127.97	163.03	180	116.05
Short-Term Investments	-	-	-	18.31	110.7	137.57
Cash & Short-Term Investments	58.85	30.79	127.97	181.34	290.71	253.62
Cash Growth	-47.07%	-75.94%	-29.43%	-37.62%	14.62%	167.48%
Receivables	2.76	2.07	-	-	-	9.39
Prepaid Expenses	4.47	5.81	8.05	13.42	12.92	5.77
Other Current Assets	-	-	39.4	-	-	-
Total Current Assets	66.08	38.67	175.41	194.76	303.63	268.78
Property, Plant & Equipment	89.41	92.44	108.03	133.97	36.15	22.94
Long-Term Investments	-	-	-	-	0.5	49.83
Other Long-Term Assets	8.7	8.7	75.16	20.05	14.59	1.4
Total Assets	164.18	139.81	358.6	348.78	354.86	342.94
Accounts Payable	2.17	4.08	3.64	17.44	13.74	4.02
Accrued Expenses	6.22	10.72	22.51	25.07	24	14.23
Current Portion of Long-Term Debt	-	-	-	0.46	-	0.45
Current Portion of Leases	9.05	8.67	5.59	3.6	6.61	5.12
Current Unearned Revenue	-	-	-	4.26	16.82	22.6
Other Current Liabilities	13.89	17.75	66.92	34.77	21.1	-
Total Current Liabilities	31.32	41.22	98.66	85.6	82.26	46.42
Long-Term Debt	-	-	101.54	50.59	24.64	24.64
Long-Term Leases	80.5	82.97	91.65	107.94	17.96	10.56
Long-Term Unearned Revenue	-	-	-	92.43	87	85.57
Other Long-Term Liabilities	1.9	1.84	111.6	1.44	11.5	1
Total Liabilities	113.72	126.03	403.46	338	223.35	168.19
Common Stock	0.01	0.17	0.14	0.13	0.09	0.09
Additional Paid-In Capital	995.87	991.71	933.24	875.18	745.83	723.48
Retained Earnings	-945.42	-978.1	-978.24	-864.51	-614.35	-548.78
Comprehensive Income & Other	-	-	-	-0.01	-0.06	-0.05
Total Common Equity	50.47	13.78	-44.86	10.78	131.51	174.75
Shareholders' Equity	50.47	13.78	-44.86	10.78	131.51	174.75
Total Liabilities & Equity	164.18	139.81	358.6	348.78	354.86	342.94
Total Debt	89.55	91.64	198.78	162.59	49.21	40.77
Net Cash (Debt)	-30.7	-60.85	-70.82	18.75	241.5	212.85
Net Cash Growth	-	-	-	-92.23%	13.46%	325.39%
Net Cash Per Share	-3.78	-7.83	-11.07	3.47	52.67	53.35
Filing Date Shares Outstanding	8.73	8.72	7.55	6.3	4.6	4.58
Total Common Shares Outstanding	8.73	8.65	6.75	6.26	4.59	4.57
Working Capital	34.76	-2.55	76.75	109.17	221.37	222.36
Book Value Per Share	5.78	1.59	-6.64	1.72	28.62	38.21
Tangible Book Value	50.47	13.78	-44.86	10.78	131.51	174.75
Tangible Book Value Per Share	5.78	1.59	-6.64	1.72	28.62	38.21
Machinery	33	32.92	33.09	31.58	23.61	19.89
Construction In Progress	0.87	0.86	1.11	3.97	1.67	0.35
Leasehold Improvements	30.95	30.95	32.49	32.47	32.93	27.98

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q